Mosunetuzumab

Therapeutic Mosunetuzumab antibody from the original Lunsumio® commercial drug.

Reference Standard as Aliquots

Lunsumio®
Filters Sort results
Reset Apply
Product batch
Expiry date
Brand & Origin
Price
1. Select quantity range
2. Your quantity
Date to be defined
Lunsumio®
DE
316,00  /mg
Select quantity:
Max:
Min: 7
Step: 1
Max:
Min: 7
Step: 1
mg

Biosimilars as Aliquots​

Filters Sort results
Reset Apply
No results found. Clear filters and try again?

Batch specific analytical data available

Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API). ​

Request an individual offer​

+ download a free sample​

1. Choose your(s) method(s) of interest
2. Provide your contact details
3. Send us your request and download a free sample report


Please provide your contact information


send us your inquiry and download a free sample file


Product Information

Here you will find the product information for the reference product.

Lunsumio® / Mosunetuzumab Reference Product

Drug nameLunsumio®
INNMosunetuzumab
API typeMosunetuzumab is a full-length, humanized anti-CD20/CD3 immunoglobulin (Ig)G1 isotype that is
produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic agents; other antineoplastic agents; monoclonal
antibodies
ATC code
L01FX25
Target of antibody
CD20, CD3
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Mosunetuzumab is an anti-CD20/CD3 T-cell engaging bispecific antibody targeting CD20-expressing
B-cells. It is a conditional agonist; targeted B-cell killing is observed only upon simultaneous binding
to CD20 on B-cells and CD3 on T-cells. Engagement of both arms of mosunetuzumab results in the
formation of an immunologic synapse between a target B cell and a cytotoxic T cell leading to T-cell
activation. Subsequent directed release of perforin and granzymes from T-cell activation through the
immunologic synapsis induce B-cell lysis leading to cell death.
Lunsumio caused B-cell depletion (defined as CD19 B-cell counts < 0.07 x 109
/L) and
hypogammaglobulinemia (defined as IgG levels < 500 mg/dL).
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/22/1649/001
EU/1/22/1649/002
Marketing authorisation holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Name of the manufacturer of the biological active substance
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
USA
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4058 Basel
Switzerland
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
GERMANY
Max shelf life
3 years
Diluted solution
Chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C - 8 °C and 24 hours
at 9 °C - 30 °C.
From a microbiological point of view, the product should be used immediately. If not used
immediately, in-use storage times and conditions are the responsibility of the user and would normally
not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated
aseptic conditions.
Storage conditions
2°C – 8°C
List of excipients
L-histidine
L-methionine
Acetic acid (pH adjustment)
Sucrose
Polysorbate 20 (E 432)
Water for injections

Support

Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.

How the ordering process works:

1 – Create your wishlist by adding the molecules you need.

2 – Export your wishlist as a PDF or send it to Evidentic.

3 – Receive a non-binding quote within 24 hours.

Frequently asked questions​

At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.

Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.

If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.

But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.

And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.

Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!

Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like:

  • Use as reference molecules for your assays
  • In functional in-vitro assays
  • For analytical procedures
  • For biosimilar and new drug early development
  • To compare against your research-grade molecules

Looking for a specific molecule?

Have a question?

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.